InspireMD (NYSE:NSPR) Director Purchases $17,600.00 in Stock

InspireMD, Inc. (NYSE:NSPR) Director Paul Stuka acquired 20,000 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were purchased at an average price of $0.88 per share, with a total value of $17,600.00. Following the completion of the acquisition, the director owned 667,871 shares in the company, valued at approximately $587,726.48. The trade was a 3.09% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Paul Stuka also recently made the following trade(s):

• On Monday, May 11th, Paul Stuka acquired 10,000 shares of InspireMD stock. The shares were purchased at an average price of $1.19 per share, with a total value of $11,900.00.
• On Friday, May 8th, Paul Stuka acquired 65,626 shares of InspireMD stock. The shares were purchased at an average price of $1.16 per share, with a total value of $76,126.16.
• On Thursday, May 7th, Paul Stuka acquired 6,378 shares of InspireMD stock. The shares were purchased at an average price of $1.15 per share, with a total value of $7,334.70.
• On Wednesday, May 6th, Paul Stuka acquired 1,517 shares of InspireMD stock. The shares were purchased at an average price of $1.12 per share, with a total value of $1,699.04.

InspireMD Stock Up 2.2%

Shares of NSPR stock traded up $0.02 on Friday, reaching $0.92. 252,508 shares of the stock were exchanged, compared to its average volume of 183,683. The stock has a market cap of $43.09 million, a P/E ratio of -1.23 and a beta of 0.82. The firm has a 50 day moving average of $1.32 and a two-hundred day moving average of $1.63. InspireMD, Inc. has a 1-year low of $0.86 and a 1-year high of $2.93.

Analyst Upgrades and Downgrades

Several research analysts have commented on NSPR shares. Lake Street Capital set a $4.00 price objective on InspireMD in a research report on Monday, May 4th. Maxim Group began coverage on InspireMD in a research report on Monday, February 2nd. They issued a “buy” rating and a $6.00 target price for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Finally, Loop Capital set a $5.00 target price on InspireMD in a research report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, InspireMD currently has an average rating of “Buy” and an average price target of $4.50.

Institutional Trading of InspireMD

Large investors have recently modified their holdings of the business. XTX Topco Ltd acquired a new stake in shares of InspireMD during the fourth quarter valued at about $30,000. Renaissance Technologies LLC acquired a new stake in shares of InspireMD during the first quarter valued at about $29,000. Virtu Financial LLC acquired a new stake in shares of InspireMD during the fourth quarter valued at about $31,000. Creative Planning acquired a new stake in shares of InspireMD during the second quarter valued at about $44,000. Finally, Uniting Wealth Partners LLC acquired a new stake in shares of InspireMD during the third quarter valued at about $51,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.